Cargando…
Percutaneous thrombectomy in patients with intermediate- and high-risk pulmonary embolism and contraindications to thrombolytics: a systematic review and meta-analysis
Catheter-directed interventions have slowly been gaining ground in the treatment of pulmonary embolism (PE), especially in patients with increased risk of bleeding. The goal of this study is to summarize the evidence for the efficacy and safety of percutaneous thrombectomy (PT) in patients with cont...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762655/ https://www.ncbi.nlm.nih.gov/pubmed/36536090 http://dx.doi.org/10.1007/s11239-022-02750-1 |
_version_ | 1784852908027674624 |
---|---|
author | Milioglou, Ioannis Farmakis, Ioannis Wazirali, Mohannad Ajluni, Steven Khawaja, Tasveer Chatuverdi, Abhishek Giannakoulas, George Shishehbor, Mehdi Li, Jun |
author_facet | Milioglou, Ioannis Farmakis, Ioannis Wazirali, Mohannad Ajluni, Steven Khawaja, Tasveer Chatuverdi, Abhishek Giannakoulas, George Shishehbor, Mehdi Li, Jun |
author_sort | Milioglou, Ioannis |
collection | PubMed |
description | Catheter-directed interventions have slowly been gaining ground in the treatment of pulmonary embolism (PE), especially in patients with increased risk of bleeding. The goal of this study is to summarize the evidence for the efficacy and safety of percutaneous thrombectomy (PT) in patients with contraindications to systemic and local thrombolysis. We performed a systematic review and meta-analysis using MEDLINE, Cochrane, Scopus and the Web of Science databases for studies from inception to March 2022. We included patients with intermediate- and high-risk PE with contraindications to thrombolysis; patients who received systematic or local thrombolysis were excluded. Primary endpoint was in-hospital and 30-day mortality, with secondary outcomes based on hemodynamic and radiographic changes. Major bleeding events were assessed as a safety endpoint. Seventeen studies enrolled 455 patients, with a mean age of 58.6 years and encompassing 50.4% females. In-hospital and 30-day mortality rates were 4% (95% CI 3–6%) and 5% (95% CI 3–9%) for all-comers, respectively. We found a post-procedural reduction in systolic and mean pulmonary arterial pressures by 15.4 mmHg (95% CI 7–23.7) and 10.3 mmHg (95% CI 3.1–17.5) respectively. The RV/LV ratio and Miller Index were reduced by 0.42 (95% CI 0.38–46) and 7.8 (95% CI 5.2–10.5). Major bleeding events occurred in 4% (95% CI 3–6%). This is the first meta-analysis to report pooled outcomes on PT in intermediate- and high-risk PE patients without the use of systemic or local thrombolytics. The overall mortality rate is comparable to other contemporary treatments, and is an important modality particularly in those with contraindications for adjunctive thrombolytic therapy. Further studies are needed to understand the interplay of anticoagulation with PT and catheter-directed thrombolysis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11239-022-02750-1. |
format | Online Article Text |
id | pubmed-9762655 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-97626552022-12-20 Percutaneous thrombectomy in patients with intermediate- and high-risk pulmonary embolism and contraindications to thrombolytics: a systematic review and meta-analysis Milioglou, Ioannis Farmakis, Ioannis Wazirali, Mohannad Ajluni, Steven Khawaja, Tasveer Chatuverdi, Abhishek Giannakoulas, George Shishehbor, Mehdi Li, Jun J Thromb Thrombolysis Article Catheter-directed interventions have slowly been gaining ground in the treatment of pulmonary embolism (PE), especially in patients with increased risk of bleeding. The goal of this study is to summarize the evidence for the efficacy and safety of percutaneous thrombectomy (PT) in patients with contraindications to systemic and local thrombolysis. We performed a systematic review and meta-analysis using MEDLINE, Cochrane, Scopus and the Web of Science databases for studies from inception to March 2022. We included patients with intermediate- and high-risk PE with contraindications to thrombolysis; patients who received systematic or local thrombolysis were excluded. Primary endpoint was in-hospital and 30-day mortality, with secondary outcomes based on hemodynamic and radiographic changes. Major bleeding events were assessed as a safety endpoint. Seventeen studies enrolled 455 patients, with a mean age of 58.6 years and encompassing 50.4% females. In-hospital and 30-day mortality rates were 4% (95% CI 3–6%) and 5% (95% CI 3–9%) for all-comers, respectively. We found a post-procedural reduction in systolic and mean pulmonary arterial pressures by 15.4 mmHg (95% CI 7–23.7) and 10.3 mmHg (95% CI 3.1–17.5) respectively. The RV/LV ratio and Miller Index were reduced by 0.42 (95% CI 0.38–46) and 7.8 (95% CI 5.2–10.5). Major bleeding events occurred in 4% (95% CI 3–6%). This is the first meta-analysis to report pooled outcomes on PT in intermediate- and high-risk PE patients without the use of systemic or local thrombolytics. The overall mortality rate is comparable to other contemporary treatments, and is an important modality particularly in those with contraindications for adjunctive thrombolytic therapy. Further studies are needed to understand the interplay of anticoagulation with PT and catheter-directed thrombolysis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11239-022-02750-1. Springer US 2022-12-19 2023 /pmc/articles/PMC9762655/ /pubmed/36536090 http://dx.doi.org/10.1007/s11239-022-02750-1 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Milioglou, Ioannis Farmakis, Ioannis Wazirali, Mohannad Ajluni, Steven Khawaja, Tasveer Chatuverdi, Abhishek Giannakoulas, George Shishehbor, Mehdi Li, Jun Percutaneous thrombectomy in patients with intermediate- and high-risk pulmonary embolism and contraindications to thrombolytics: a systematic review and meta-analysis |
title | Percutaneous thrombectomy in patients with intermediate- and high-risk pulmonary embolism and contraindications to thrombolytics: a systematic review and meta-analysis |
title_full | Percutaneous thrombectomy in patients with intermediate- and high-risk pulmonary embolism and contraindications to thrombolytics: a systematic review and meta-analysis |
title_fullStr | Percutaneous thrombectomy in patients with intermediate- and high-risk pulmonary embolism and contraindications to thrombolytics: a systematic review and meta-analysis |
title_full_unstemmed | Percutaneous thrombectomy in patients with intermediate- and high-risk pulmonary embolism and contraindications to thrombolytics: a systematic review and meta-analysis |
title_short | Percutaneous thrombectomy in patients with intermediate- and high-risk pulmonary embolism and contraindications to thrombolytics: a systematic review and meta-analysis |
title_sort | percutaneous thrombectomy in patients with intermediate- and high-risk pulmonary embolism and contraindications to thrombolytics: a systematic review and meta-analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762655/ https://www.ncbi.nlm.nih.gov/pubmed/36536090 http://dx.doi.org/10.1007/s11239-022-02750-1 |
work_keys_str_mv | AT milioglouioannis percutaneousthrombectomyinpatientswithintermediateandhighriskpulmonaryembolismandcontraindicationstothrombolyticsasystematicreviewandmetaanalysis AT farmakisioannis percutaneousthrombectomyinpatientswithintermediateandhighriskpulmonaryembolismandcontraindicationstothrombolyticsasystematicreviewandmetaanalysis AT waziralimohannad percutaneousthrombectomyinpatientswithintermediateandhighriskpulmonaryembolismandcontraindicationstothrombolyticsasystematicreviewandmetaanalysis AT ajlunisteven percutaneousthrombectomyinpatientswithintermediateandhighriskpulmonaryembolismandcontraindicationstothrombolyticsasystematicreviewandmetaanalysis AT khawajatasveer percutaneousthrombectomyinpatientswithintermediateandhighriskpulmonaryembolismandcontraindicationstothrombolyticsasystematicreviewandmetaanalysis AT chatuverdiabhishek percutaneousthrombectomyinpatientswithintermediateandhighriskpulmonaryembolismandcontraindicationstothrombolyticsasystematicreviewandmetaanalysis AT giannakoulasgeorge percutaneousthrombectomyinpatientswithintermediateandhighriskpulmonaryembolismandcontraindicationstothrombolyticsasystematicreviewandmetaanalysis AT shishehbormehdi percutaneousthrombectomyinpatientswithintermediateandhighriskpulmonaryembolismandcontraindicationstothrombolyticsasystematicreviewandmetaanalysis AT lijun percutaneousthrombectomyinpatientswithintermediateandhighriskpulmonaryembolismandcontraindicationstothrombolyticsasystematicreviewandmetaanalysis |